TRANSlational Cancer Oesophagus Gefitinib study (TRANS-COG)

Qualification of predictive biomarkers for epidermal growth factor receptor tyrosine kinase inhibitor therapy in oesophagogastric adenocarcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN32435732

Enrollment

300

Registered

2012-03-05

Start date

2011-09-01

Completion date

Unknown

Last updated

2018-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper Gastro-Intestinal Cancer Cancer Malignant neoplasm of oesophagus

Interventions

EGFR pathway analysis Mutational analysis of EGFR, KRAS, BRAF and PIK3CA and EGFR FISH

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with oesophagogastric cancer must be eligible for and enrolled in the COG trial 2. Ability to provide written informed consent 3. Formalin-fixed and paraffin-embedded (FFPE) tumour material available 4. Male and female participants 5. Lower Age Limit 18 years

Exclusion criteria

Exclusion criteria: 1. Patients not enrolled in COG trial 2. Inability to provide written informed consent 3. No FFPE tumour material available for analysis

Design outcomes

Primary

Measure	Time frame
Overall survival in different biomarker groups	—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 8, 2026